Format

Send to

Choose Destination
Blood. 2018 Sep 6;132(10):1007-1012. doi: 10.1182/blood-2018-03-828269. Epub 2018 Jul 23.

BCL-2 inhibition in AML: an unexpected bonus?

Author information

1
The University of Texas MD Anderson Cancer Center, Houston, TX; and.
2
Dana-Farber Cancer Institute, Boston, MA.

Abstract

B-cell lymphoma 2 (BCL-2) was discovered at the breakpoint of the t(14;18) in follicular lymphoma >30 years ago. Although inhibition of BCL-2 first proved valuable in lymphoid malignancies, clinical progress in myeloid malignancies lagged. Here, we summarize the basic biology and preclinical results that spurred clinical BCL-2 inhibition in acute myeloid leukemia (AML). Response rates and toxicity for venetoclax in combination with standard AML agents, such as azacitidine, decitabine, and low-dose cytarabine, compare favorably with conventional induction chemotherapy. Durability of response requires further study.

PMID:
30037885
PMCID:
PMC6235069
[Available on 2019-09-06]
DOI:
10.1182/blood-2018-03-828269

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center